Portal Hypertension-Related Digestive Hemorrhage in Patients with Pancreatic Neuroendocrine Tumors Abstract #1901
Introduction: Pancreatic neuroendocrine tumors (pNET) can cause portal hypertension (PHT)
Aim(s): Describe patients with pNET and PHT-related digestive hemorrhage (PHT-DH)
Materials and methods: Monocentric retrospective study from 2003 to 2016 of all consecutive patients with pNET who had PHT-DH. PHT was defined on CT-scan by thrombosis or encasement of mesenteric, portal or splenic veins
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Nelly Muller
Authors: Muller N, Zappa M, Hammel P, De Mestier L, Laurent L, Levy P, Jais B, Ruszniewski P, Hentic O
Keywords: portal hypertension
To read results and conclusion, please login ...
Further abstracts you may be interested in
#706 Is There a Therapeutic Impact of Segmental Portal Hypertension on Advanced Pancreatic Neuroendocrine Tumors?
Introduction: Well-differenciated locally advanced Pancreatic Neuroendocrine Tumors (PNET) lead to significant local complications due to segmental portal hypertension (SPH).
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Dr Frédéric Dumont
#1295 Intra-Operative Portal Vein Insulin Assay Combined with Occlusion of the Pancreas for Complicated Pancreatogenous Hypoglycemia
Introduction: Pancreatogenous hypoglycemia is a rare endocrine disorder. The precise localization of hypersecreting tissue and determination of complete resection are two main challenges for complicated pancreatogenous hypoglycemia, such as multiple endocrine neoplasia syndromes type-1 (MEN-1) and nesidioblastosis.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: Yang Zhiying
#913 A PCR-Based Multigene Transcript Analysis Blood Test Outperforms Chromogranin A in the Detection of Gastrointestinal and Pancreatic Neuroendocrine Tumors and is Unaffected by PPI Use or Hypertension
Introduction: A critical requirement in the management of gut NETs is a blood biomarker test that is sensitive, specific and reproducible.
Conference: 11th Annual ENETS Conference (2014)
Presenting Author: Professor Irvin M Modlin
Introduction: Acromegaly leads to reduced life expectancy, with an increase in the mortality rate. From several retrospective cohort studies, the predominant outcome is serum growth hormone (GH) concentration. Other factors associated with increased mortality include duration of symptoms prior to diagnosis, duration of disease, older age at diagnosis and the presence of cardiovascular disease, diabetes mellitus (DM) and hypertension at diagnosis.
Conference: 7th Annual ENETS Conference (2010)
Presenting Author: OKH OKSANA OLEGOVNA KHYZHNYAK
Introduction: NETs are highly vascularized neoplasms overexpressing VEGF as well as VEGFR. Axitinib is a TKI with selective picomolar potency against VEGFR-1, -2 and -3
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Mauro Cives